Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+T-lymphocytes

Naarding, Marloes A.; Baan, Elly; Pollakis, Georgios; Paxton, William A.

doi:10.1186/1742-4690-4-6

Cited by 55 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CQ had an additive effect against HIV-1 when used in combination with other antiretroviral agents [155,156]. Naarding et al demonstrated that CQ reduced HIV-1 transmission to and replication in CD4 + T-lymphocytes [157]. Similarly, Martinson et al observed that CQ had a preventive role in HIV infection, reducing CD8 + T cell activation upon HIV replication [158].…”

Section: Chloroquine and Hydroxychloroquine And Hivmentioning

confidence: 99%

“…Coronaviridae CoV Chloroquine in vitro [145][146][147] Picornaviridae Enteroviruses Chloroquine in vitro [160] Chloroquine in vitro/in vivo (mouse) [161] Filoviridae EBOV Chloroquine in vitro [142,143] in vivo [142] Artesunate, amodiaquine in vivo [58] Mefloquine in vitro [132] Retroviridae HIV Artemisinin in vitro [23] Doxycycline in vitro [23] Mefloquine, toremifene, posaconazole in vitro [132] Chloroquine in vitro [151,157,158] in vivo [155] Chloroquine, hydroxychloroquine in vitro [152][153][154]156] Phenuiviridae SFTSV Amodiaquine In vitro [163] Among the aryl-aminoalcohols, the use of MQ in the treatment of JCPyV infection has been extensive, although with contradictory outcomes. Among the aminoquinolines, both CQ and hydroxyCQ showed promising results in reducing the replication of some emerging viruses, such as DENV and ZIKV.…”

Section: Virus Family Virus Species Drug Type Of Study (Model) Referementioning

confidence: 99%

See 1 more Smart Citation

The Use of Antimalarial Drugs against Viral Infection

et al. 2020

View full text Add to dashboard Cite

In recent decades, drugs used to treat malaria infection have been shown to be beneficial for many other diseases, including viral infections. In particular, they have received special attention due to the lack of effective antiviral drugs against new emerging viruses (i.e., HIV, dengue virus, chikungunya virus, Ebola virus, etc.) or against classic infections due to drug-resistant viral strains (i.e., human cytomegalovirus). Here, we reviewed the in vitro/in vivo and clinical studies conducted to evaluate the antiviral activities of four classes of antimalarial drugs: Artemisinin derivatives, aryl-aminoalcohols, aminoquinolines, and antimicrobial drugs.

show abstract

Section: Chloroquine and Hydroxychloroquine And Hivmentioning

confidence: 99%

Section: Virus Family Virus Species Drug Type Of Study (Model) Referementioning

confidence: 99%

The Use of Antimalarial Drugs against Viral Infection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Renewed interest in chloroquine has emerged after recent reports of its effectiveness in reducing viral loads of HIV-1 (1,2). Despite its widespread use, chloroquine has a very narrow margin of safety.…”

mentioning

confidence: 99%

The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel

Rodríguez-Menchaca

Navarro‐Polanco

Ferrer-Villada

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

123

135

View full text Add to dashboard Cite

Although chloroquine remains an important therapeutic agent for treatment of malaria in many parts of the world, its safety margin is very narrow. Chloroquine inhibits the cardiac inward rectifier K ؉ current IK1 and can induce lethal ventricular arrhythmias. In this study, we characterized the biophysical and molecular basis of chloroquine block of Kir2.1 channels that underlie cardiac I K1. The voltage-and K ؉ -dependence of chloroquine block implied that the binding site was located within the ion-conduction pathway. Site-directed mutagenesis revealed the location of the chloroquine-binding site within the cytoplasmic pore domain rather than within the transmembrane pore. Molecular modeling suggested that chloroquine blocks Kir2.1 channels by plugging the cytoplasmic conduction pathway, stabilized by negatively charged and aromatic amino acids within a central pocket. Unlike most ionchannel blockers, chloroquine does not bind within the transmembrane pore and thus can reach its binding site, even while polyamines remain deeper within the channel vestibule. These findings explain how a relatively low-affinity blocker like chloroquine can effectively block I K1 even in the presence of high-affinity endogenous blockers. Moreover, our findings provide the structural framework for the design of safer, alternative compounds that are devoid of Kir2.1-blocking properties.IK1 ͉ ion channel ͉ KCNJ2 ͉ malaria ͉ polyamines

show abstract

“…Nalidixic acid and chloroquine share structural features being essential for their antibacterial and antiparasitic activity, respectively. Apart from its well-known antimalarial effects [2][3][4], chloroquine exerts direct antiviral [5][6][7][8][9][10][11][12][13], antifungal [13][14][15][16], and antibacterial effects [13,[17][18][19][20]. Furthermore, chloroquine exhibits immunomodulatory activity [21][22][23][24][25] and was found to reverse P-glycoprotein (P-gp)-mediated multidrug resistance, thereby increasing the cytotoxicity of some antineoplastic agents [26][27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Dalhoff¹

2014

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

This review summarizes evidence that commercially available fluoroquinolones used for the treatment of bacterial infections are active against other non-bacterial infectious agents as well. Any of these fluoroquinolones exerts, in parallel to its antibacterial action, antiviral, antifungal, and antiparasitic actions at clinically achievable concentrations. This broad range of anti-infective activities is due to one common mode of action, i.e., the inhibition of type II topoisomerases or inhibition of viral helicases, thus maintaining the selective toxicity of fluoroquinolones inhibiting microbial topoisomerases at low concentrations but mammalian topoisomerases at much higher concentrations. Evidence suggests that standard doses of the fluoroquinolones studied are clinically effective against viral and parasitic infections, whereas higher doses administered topically were active against Candida spp. causing ophthalmological infections. Well-designed clinical studies should be performed to substantiate these findings.

show abstract

Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+T-lymphocytes

Cited by 55 publications

References 40 publications

The Use of Antimalarial Drugs against Viral Infection

The Use of Antimalarial Drugs against Viral Infection

The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel

Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Contact Info

Product

Resources

About